OOIR: Observatory of International Research

Papers

(The TQCC of British Journal of Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	111
Updates on targeted therapies for acute myeloid leukaemia	95
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry	94
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation	93
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma	92
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations	84
Disseminated intravascular coagulation: epidemiology, biomarkers, and management	80
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies	80
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy	74
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination	73
Impact of COVID‐19 on red blood cell rheology	69
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity	67
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma	65
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?	60
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience	58
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies	58
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	57
MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a pros	55
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells	53
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies	53
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye	52
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients	52
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold	50
Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes	49
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients	49

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant	46
Thrombophilia testing: A British Society for Haematology guideline	46
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations	45
COVID‐19 and immunothrombosis: emerging understanding and clinical management	44
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres	44
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis	43
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	43
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study	42
Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders	41
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome	41
Haematological management of major haemorrhage: a British Society for Haematology Guideline	41
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	41
Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia	39
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials	39
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries	39
Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood	38
Identification of CXCL12‐abundant reticular cells in human adult bone marrow	38
Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort s	38
Thrombosis in immune thrombocytopenia — current status and future perspectives	37
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches	37
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline	36
Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges	36
Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline	36
Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children	35
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future	34
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine	34
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients	34
Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience	34
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	34
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy	33
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia	33
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics	32
Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flo	32
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity	32
Impact of major bleeding and thrombosis on 180‐day survival in patients with severe COVID‐19 supported with veno‐venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observa	32
Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trial	31
Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease	30
Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease	30
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study	30
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) wi	30
A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation	29
von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate‐to‐severe COVID‐19 patients	29
Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms	28
Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study	28
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study	28
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline	28
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients	28
Vasculo‐toxic and pro‐inflammatory action of unbound haemoglobin, haem and iron in transfusion‐dependent patients with haemolytic anaemias	28
Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation	28
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study	28

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination	27
COVID‐19 associated Kikuchi‐Fujimoto disease	26
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia	26
Current and future therapies for haemophilia—Beyond factor replacement therapies	26
Are mushroom‐shaped erythrocytes an indicator of COVID‐19?	26
Absence of hydroxyurea‐induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia	24
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy	24
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study	24
Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma	24
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients	24
Novel therapies for immune thrombocytopenia	24
Second primary malignancy in myelofibrosis patients treated with ruxolitinib	24
Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities	23
Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency	23
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before	23
The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma	23
First use of the anti‐VWF nanobody caplacizumab to treat iTTP in pregnancy	22
Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features	22
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial	22
Adoptive immunotherapy with double‐bright (CD56^bright/CD16^bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concep	22
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy	22
Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results	22
Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline	21
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma	21
Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres	21
Plasma microparticles of intubated COVID‐19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine‐dependent manner	21
Guideline for the first‐line management of Classical Hodgkin Lymphoma — A British Society for Haematology guideline	21
Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study	21
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders	21
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent	21
Efficacy and safety of intravitreal methotrexate for vitreo‐retinal lymphoma – 20 years of experience	21
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*	21
Sickle cell disease: progress towards combination drug therapy	21
Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	21
Safety of anti‐SARS‐CoV‐2 vaccination for patients with immune thrombocytopenia	20
Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab	20
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019	20
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses	20
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma	20
Unanswered questions in cancer‐associated thrombosis	20
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with si	20
The NICE COVID‐19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact	20
Haemophilia: factoring in new therapies	20
Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients	20
Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID‐19 in immunocompromised patients	19
Reduced‐dose post‐transplant cyclophosphamide plus low‐dose post‐transplant anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis with fludarabine–busulfan–cytarabine conditioning in haploi	19
Early integration of palliative care for patients with haematological malignancies	19
Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia	19
Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies	19
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure	19
Guideline for the treatment of chronic lymphocytic leukaemia	19
EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features	19
Saving lives through early diagnosis: the promise and role of point of care testing for sickle cell disease	19
Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation	19
Mitochondria transfer from early stages of erythroblasts to their macrophage niche via tunnelling nanotubes	19
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study	19
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients	18
Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart rev	18
Gene therapy for primary immunodeficiencies	18
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report	18
Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021	18
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies	18
Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response	18
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant	18
SLN124, a GalNac‐siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron‐overload in a mouse model of β‐thalassaemi	18
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia	18
Front‐line management of post‐transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline	18
Molecular dynamics of targeting CD38 in multiple myeloma	17
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia	17
Daratumumab in rituximab‐refractory autoimmune haemolytic anaemia	17
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series	17
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	17
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma	17
Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia	17
Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma	17
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies	17
Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias	17
Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan	17
Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma	17
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms	17

Deficient mitophagy pathways in sickle cell disease	16
Post‐transplant lymphoproliferative disorder: Update on treatment and novel therapies	16
British Society for Haematology Guidelines on transfusion for fetuses, neonates and older children (Br J Haematol. 2016;175:784–828). Addendum August 2020	16
A case of severe aplastic anaemia after SARS‐CoV‐2 vaccination	16
Cognitive performance as a predictor of healthcare transition in sickle cell disease	16
Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID‐19 while we are awaiting the results of clinical trials?	16
Transfusion management of severe anaemia in African children: a consensus algorithm	16
Thalassaemia—A global view	16
The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies	16
How I treat triple‐class refractory multiple myeloma	16
The wider perspective: cord blood banks and their future prospects	16
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia	16
Oncolytic herpes simplex virus type 1 (HSV‐1) in combination with lenalidomide for plasma cell neoplasms	16
COVID‐19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience	16
Management of cardiovascular complications of bruton tyrosine kinase inhibitors	16
The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma	16
A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma	16
Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma	16
Haemoglobin response to senicapoc in patients with sickle cell disease: a re‐analysis of the Phase III trial	15
Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens	15
The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b2	15
Plasma protein and venous thromboembolism: prospective cohort and mendelian randomisation analyses	15
Monocyte–macrophage polarization and recruitment pathways in the tumour microenvironment of B‐cell acute lymphoblastic leukaemia	15
Alpha‐defensins: risk factor for thrombosis in COVID‐19 infection	15
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine	15
Screening and monitoring of the BTK^C481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy	15
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies	15
B‐cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification	15
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID‐19) pandemic: selection criteria and patients’ satisfaction	15
The incidence and type of cancer in patients with ataxia‐telangiectasia via a retrospective single‐centre study	15
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia	15
Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant	15
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity	15
Infiltration of CD163‐, PD‐L1‐ and FoxP3‐positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors	15
Liquid biopsy: a non‐invasive approach for Hodgkin lymphoma genotyping	15
Case report: Up‐front allogeneic stem cell transplantation in a patient with the VEXAS syndrome	15
Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study	15
Activation of circulating platelets in vaccine‐induced thrombotic thrombocytopenia and its reversal by intravenous immunoglobulin	15
Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases	15
The use of frailty assessments in treating older adults with aggressive lymphomas	15
Integrating artificial intelligence into haematology training and practice: Opportunities, threats and proposed solutions	15
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up	15
Viral hepatitis in haemophilia: historical perspective and current management	15
A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies	15
Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study	14
Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?	14
Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells	14
Cardiovascular disease in hereditary haemophilia: The challenges of longevity	14
Antithrombin III deficiency‐induced coagulopathy in the context of COVID‐19: a case series	14
A real‐world study of immune thrombocytopenia management during the COVID‐19 pandemic in the UK	14
The spectrum of splenic complications in patients with sickle cell disease in Africa: a systematic review	14
Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis	14
The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018	14
Anti‐severe acute respiratory syndrome coronavirus‐2 adenoviral‐vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers	14
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population‐based study	14
Current prophylactic plasma infusion protocols do not adequately prevent long‐term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort	14
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis	14
Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies	14
AZD1222 vaccine‐related coagulopathy and thrombocytopenia without thrombosis in a young female	14
Controversies in the use of new bone‐modifying therapies in multiple myeloma	14
Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience	14
Genetic characterisation of childhood B‐other‐acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation‐dependent Probe Amplification	14
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland	14
Characteristic vacuolisation of granulocytic and erythroid precursors associated with VEXAS syndrome	14
A multicentre double‐blind, double‐dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients	14
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes	13
The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T‐cell therapy	13
Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T‐cell therapy	13
Management of chronic myeloid leukaemia patients treated with ponatinib in a real‐life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA)	13
Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study	13
Mortality and burden of post‐COVID‐19 syndrome have reduced with time across SARS‐CoV‐2 variants in haematology patients	13
GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects	13
Increased platelet activation in SARS‐CoV‐2 infected non‐hospitalised children and adults, and their household contacts	13
Incidence of thrombotic complications in hospitalised and non‐hospitalised patients after COVID‐19 diagnosis	13
Clonally unrelated Richter syndrome are truly de novo diffuse large B‐cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome	13
The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant	13
Management of secondary central nervous system lymphoma	13
Checkpoint CD47 expression in classical Hodgkin lymphoma	13
Posters	13
UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive an	13
A randomised phaseIIstudy of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) inhigher‐Risk MDS	13
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vascul	13
Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation	13
Parameters of long‐term response with CD28‐based CD19 chimaeric antigen receptor‐modified T cells in children and young adults with B‐acute lymphoblastic leukaemia	13
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real‐life study	13
BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses	13
Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia	13
Intravenous iron: do we adequately understand the short‐ and long‐term risks in clinical practice?	13
Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma	13
Towards treatments for VEXAS	13
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial	13
Durable humoral responses after the second anti‐SARS‐CoV‐2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors	13
Point‐of‐care haemoglobin testing in African hospitals: a neglected essential diagnostic test	13
Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy	13
The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?	13